Aslan's latest cancer focus also flops, leaving just two major programs for the troubled biotech
Aslan $ASLN has stumbled back into the failure pit.
When their lead drug failed to treat gastric cancer, Aslan Pharmaceuticals announced they were going to focus on another type: biliary tract cancer (BTC). When the gastric failure forced them to cut 30% of their staff, they again emphasized the new target as one of three remaining programs.
But Aslan’s BTC trial has now failed on both primary endpoints. The results showed an improved response rate for Aslan’s varlitinib over the control arm, but not significantly. The drug arm had a progression-free survival rate of 2.83 months compared to 2.79 in the control arm — basically a one-day difference.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.